Oncotelic Featured in Editorial Highlighting Biotech's Shift Toward Science-Driven Asset Valuation

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in recent BioMedWire editorial coverage highlighting a fundamental shift in biotechnology, where scientific progress is increasingly recognized as measurable financial value rather than purely as research expenditure. As clinical-stage assets advance toward commercialization, fair-value accounting frameworks under U.S. GAAP are enabling companies to reflect pipeline progress, probability of success and timing of market entry directly on the balance sheet. Within this evolving landscape, Oncotelic exemplifies the trend through its diversified oncology pipeline and strategic holdings, including its 45% stake in GMP Bio, recently measured at an enterprise value exceeding $1 billion, demonstrating how advancing science can materially strengthen financial positioning.

The BioMedWire editorial also situates Oncotelic alongside a group of advanced biotechnology companies targeting disease at the genetic and molecular level, including Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Denali Therapeutics Inc. (NASDAQ: DNLI). These companies are advancing RNA interference, gene therapy, mRNA and targeted delivery platforms, reflecting a broader industry transition in which pipeline maturity, clinical progress and technological innovation are increasingly aligned with valuation, reinforcing the emergence of biotech innovation as a structured and investable asset class. The full editorial coverage can be accessed at https://ibn.fm/lkqkr.

This shift toward science-driven asset valuation represents a significant development for biotechnology investors and companies alike. For decades, biotech companies have struggled to communicate the value of their research pipelines to investors, with early-stage research often viewed as speculative and difficult to quantify. The adoption of fair-value accounting frameworks changes this dynamic by allowing companies to assign tangible financial value to their scientific progress based on objective criteria including clinical trial results, regulatory milestones, and market potential. This transformation enables more accurate financial reporting and provides investors with clearer insight into the true value of a company's research and development efforts.

The implications extend beyond individual company valuations to the broader biotechnology investment landscape. As scientific progress becomes more directly linked to financial metrics, investors can make more informed decisions based on standardized valuation methodologies rather than subjective assessments of scientific potential. This increased transparency and standardization could attract more institutional investment to the biotechnology sector, potentially accelerating innovation by providing companies with better access to capital. The trend also encourages companies to focus resources on the most promising scientific avenues, as successful clinical progress will be more directly reflected in financial statements and market valuations.

For Oncotelic specifically, the recognition of its stake in GMP Bio at an enterprise value exceeding $1 billion demonstrates how this valuation approach can reveal substantial hidden value within biotech companies. This valuation methodology provides a more comprehensive picture of a company's worth beyond traditional financial metrics, incorporating the potential future value of scientific assets that may not yet be generating revenue. As the biotechnology industry continues to evolve, this science-driven approach to asset valuation is likely to become increasingly important for both companies seeking to demonstrate their value and investors looking to identify promising opportunities in the sector.